Illumina Synergy Partek operates under Illumina ownership, aligning its analytics software with Illumina sequencing workflows. This creates cross-sell opportunities to Illumina's customers seeking end-to-end data analysis pipelines. Partek has a strong track record across genomics applications, which adds credibility for labs adopting Illumina platforms.

Single Cell Leadership Strong focus on single-cell analysis with pipelines such as inDrop integration and a history of partnerships in the space. This supports selling Partek Flow analytics to researchers sequencing single cells and collaborating labs seeking turnkey pipelines.

Cloud First Cloud-based analytics and mobility are central to Partek Flow, enabling scalable, remote data processing for academic labs, biotechs, and CROs that require flexible access to genomics workflows.

Clinical Pipeline Position Partek as a clinical-ready analytics option that complements genomic testing workflows, with emphasis on standardized reporting and regulatory-friendly outputs to appeal to translational and clinical labs.

Partnership Growth Leverage Partek’s history of partnerships with sequencing technology players and bioinformatics partners to expand go-to-market via co-selling with Illumina and other ecosystem collaborators, targeting research institutes and CROs.